Pfizer announced positive late-stage trial results for its oral obesity drug, showing significant weight loss comparable to injectable competitors but with a more convenient daily pill format.

Pharma Innovation

If approved, the oral treatment could disrupt the current GLP-1 duopoly, offering a scalable, lower-cost alternative that eliminates the need for cold-chain storage and injection supplies.